AR089670A1 - Forma de dosificacion que comprende nicotina solida con reduccion de los trastornos organolepticos - Google Patents

Forma de dosificacion que comprende nicotina solida con reduccion de los trastornos organolepticos

Info

Publication number
AR089670A1
AR089670A1 ARP130100043A ARP130100043A AR089670A1 AR 089670 A1 AR089670 A1 AR 089670A1 AR P130100043 A ARP130100043 A AR P130100043A AR P130100043 A ARP130100043 A AR P130100043A AR 089670 A1 AR089670 A1 AR 089670A1
Authority
AR
Argentina
Prior art keywords
reduction
dosage form
nicotine
organoleptic
disorders
Prior art date
Application number
ARP130100043A
Other languages
English (en)
Original Assignee
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ab filed Critical Mcneil Ab
Publication of AR089670A1 publication Critical patent/AR089670A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una forma de dosificación farmacéutica sólida para la liberación de nicotina en la cavidad oral comprende un núcleo encapsulado por al menos una película de revestimiento en donde el núcleo comprende nicotina y en donde la película de revestimiento comprende al menos un polímero formador de película y al menos un componente para la reducción de una o más sensaciones organolépticamente desagradables y donde al menos una película de revestimiento carece de nicotina y carece de amortiguador.
ARP130100043A 2012-01-05 2013-01-04 Forma de dosificacion que comprende nicotina solida con reduccion de los trastornos organolepticos AR089670A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE1200017 2012-01-05

Publications (1)

Publication Number Publication Date
AR089670A1 true AR089670A1 (es) 2014-09-10

Family

ID=48744083

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100043A AR089670A1 (es) 2012-01-05 2013-01-04 Forma de dosificacion que comprende nicotina solida con reduccion de los trastornos organolepticos

Country Status (19)

Country Link
US (1) US20130177646A1 (es)
EP (1) EP2800557B1 (es)
JP (1) JP6169609B2 (es)
KR (1) KR102056041B1 (es)
CN (1) CN104053433A (es)
AR (1) AR089670A1 (es)
AU (1) AU2013206983B2 (es)
BR (1) BR112014016624A8 (es)
CA (1) CA2862497C (es)
DK (1) DK2800557T3 (es)
ES (1) ES2848534T3 (es)
HK (1) HK1201448A1 (es)
HU (1) HUE053063T2 (es)
MX (1) MX370218B (es)
NZ (1) NZ626672A (es)
PH (1) PH12014501446B1 (es)
PL (1) PL2800557T3 (es)
WO (1) WO2013103318A1 (es)
ZA (1) ZA201405745B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014157264A1 (ja) * 2013-03-27 2014-10-02 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 口腔内崩壊性フィルムコーティング錠
BR112015030140A2 (pt) * 2013-06-03 2017-07-25 Mcneil Ab forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral
WO2015068058A1 (en) * 2013-11-06 2015-05-14 Rk Technology & Investments Pte. Ltd. Tobacco free 'niconuts'and the process thereof
CA2944471C (en) * 2014-04-08 2020-03-31 Philip Morris Products S.A. Nicotine formulations and methods of making the same
CN104489916B (zh) * 2014-12-02 2016-06-01 云南中烟工业有限责任公司 红醋栗提取物在卷烟中的应用
US9585835B1 (en) 2015-09-16 2017-03-07 Sansa Corporation (Barbados) Inc. Inhalable nicotine formulations and methods of making and using the same
US10149844B2 (en) 2015-09-16 2018-12-11 Philip Morris Products S.A. Inhalable nicotine formulations, and methods of making and using thereof
CA3029985A1 (en) 2016-07-05 2018-01-11 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Oral dosage form containing a fast release exterior coating
ES2975449T3 (es) 2017-05-22 2024-07-05 Johnson & Johnson Consumer Inc Forma farmacéutica de pastilla
CA3085065C (en) 2017-12-08 2023-12-05 Fertin Pharma A/S Formulations providing high nicotine concentrations
WO2019110073A1 (en) * 2017-12-08 2019-06-13 Fertin Pharma A/S Solid oral nicotine formulation
WO2019110072A1 (en) 2017-12-08 2019-06-13 Fertin Pharma A/S Nicotine tablet
GB201811926D0 (en) 2018-07-20 2018-09-05 Nicoventures Trading Ltd Aerosolisable formulation
US12116730B2 (en) * 2019-04-16 2024-10-15 Chemstone, Inc. Method of modifying polymer barrier films
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
US11672862B2 (en) 2019-12-09 2023-06-13 Nicoventures Trading Limited Oral products with reduced irritation
US12550928B2 (en) 2019-12-09 2026-02-17 Nicoventures Trading Limited Liquid oral composition
US12171872B2 (en) 2019-12-09 2024-12-24 Nicoventures Trading Limited Oral compositions and methods of manufacture
US12520867B2 (en) 2019-12-09 2026-01-13 Nicoventures Trading Limited Buffered oral compositions
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
US12151023B2 (en) 2019-12-09 2024-11-26 Nicoventures Trading Limited Oral composition with beet material
US12439952B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Moist oral compositions
US12137723B2 (en) 2019-12-09 2024-11-12 Nicoventures Trading Limited Oral products with active ingredient combinations
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US11889856B2 (en) 2019-12-09 2024-02-06 Nicoventures Trading Limited Oral foam composition
EP4072338A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Agents for oral composition
US12599160B2 (en) 2019-12-09 2026-04-14 Nicoventures Trading Limited Lipid-containing oral composition
US11883527B2 (en) 2019-12-09 2024-01-30 Nicoventures Trading Limited Oral composition and method of manufacture
JP2023504756A (ja) 2019-12-09 2023-02-06 ニコベンチャーズ トレーディング リミテッド カンナビノイドを含む口腔用製品
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US12439949B2 (en) 2019-12-09 2025-10-14 Nicoventures Trading Limited Oral compositions with reduced water activity
US12491250B2 (en) 2019-12-09 2025-12-09 Nicoventures Trading Limited Oral composition with nanocrystalline cellulose
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
SE544672C2 (en) 2020-05-07 2022-10-11 Liw Innovation Ab New compositions for oral or nasal use
CA3181912A1 (en) 2020-06-08 2021-12-16 Anthony Richard Gerardi Effervescent oral composition comprising an active ingredient
US11839602B2 (en) 2020-11-25 2023-12-12 Nicoventures Trading Limited Oral cannabinoid product with lipid component
US20220387328A1 (en) * 2021-06-04 2022-12-08 Glaxosmithkline Consumer Healthcare Holdings (Us) Llc Dosage form for nicotine replacement therapy
MX2023015529A (es) 2021-06-25 2024-03-05 Nicoventures Trading Ltd Productos orales y metodo de fabricacion.
JP2024530905A (ja) 2021-07-30 2024-08-27 ニコベンチャーズ トレーディング リミテッド 微結晶性セルロースを含むエアロゾル生成基材
US20230109240A1 (en) * 2021-09-30 2023-04-06 L'oreal Compositions and methods for styling hair
CA3233375A1 (en) 2021-09-30 2023-04-06 Michael Zawadzki Oral product with a basic amine and an ion pairing agent
CN117256920A (zh) * 2023-09-27 2023-12-22 东莞市吉纯生物技术有限公司 一种固体雾化物及其制备方法
DK202430540A1 (en) * 2024-09-12 2026-03-26 Fertin Pharma As Orally disintegrating nicotine tablet with reduced sweetener content

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1219291A (en) * 1910-12-13 1917-03-13 Chester Earl Gray Process of manufacturing products from milk and cream.
GB2230439A (en) * 1989-04-20 1990-10-24 Alec Stanley Walter Shaw Nicotine lozenges
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
JP3707798B2 (ja) * 1996-05-13 2005-10-19 ノバルティス・コンシューマー・ヘルス・ソシエテ・アノニム 口内薬剤輸送系
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
US6583160B2 (en) * 1999-04-14 2003-06-24 Steve Smith Nicotine therapy method and oral carrier for assuaging tobacco-addiction
JP4044709B2 (ja) * 1999-11-19 2008-02-06 信越化学工業株式会社 水系フィルムコーティング剤及び経口固形製剤
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
US20020119196A1 (en) * 2000-12-21 2002-08-29 Narendra Parikh Texture masked particles containing an active ingredient
SE0102197D0 (sv) * 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
US20030118653A1 (en) * 2001-07-06 2003-06-26 Lavipharm Laboratories Inc. Quick dissolving oral mucosal drug delivery device with moisture barrier coating
JP5089840B2 (ja) * 2001-09-25 2012-12-05 救急薬品工業株式会社 ニコチン含有フィルム製剤
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
SG108299A1 (en) * 2002-06-11 2005-01-28 Inst Data Storage Method and apparatus for forming periodic structures
PT1578422E (pt) * 2002-12-20 2007-06-14 Niconovum Ab Material particulado contendo nicotina fisicamente e quimicamente estável
US20040151771A1 (en) * 2003-02-04 2004-08-05 Gin Jerry B. Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth
US7022750B2 (en) * 2003-04-04 2006-04-04 Ppg Industries Ohio, Inc. Anti-fouling coating containing copper and graphite
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US20070269492A1 (en) * 2006-05-16 2007-11-22 Per Steen New product and use and manufacture thereof
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
US20080286340A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered nicotine containing products
WO2009141321A2 (en) * 2008-05-21 2009-11-26 Novartis Ag Tablettable chewing gums
DK2296486T3 (en) * 2008-05-26 2015-07-13 Fertin Pharma As Film-coated compressed gum
ES2592882T3 (es) * 2008-10-14 2016-12-02 Mcneil Ab Forma de dosificación intra-oral de múltiples porciones y uso de la misma
EP2233134A1 (en) * 2009-03-27 2010-09-29 McNeil AB Multi-portion intra-oral dosage form with organoleptic properties
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
US20110268809A1 (en) * 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions

Also Published As

Publication number Publication date
BR112014016624A8 (pt) 2017-07-04
EP2800557A4 (en) 2015-09-09
KR20140108728A (ko) 2014-09-12
KR102056041B1 (ko) 2019-12-16
ES2848534T3 (es) 2021-08-10
MX2014008271A (es) 2014-10-06
EP2800557B1 (en) 2020-12-30
PL2800557T3 (pl) 2021-06-14
RU2623018C2 (ru) 2017-06-21
NZ626672A (en) 2016-11-25
CA2862497A1 (en) 2013-07-11
HUE053063T2 (hu) 2021-06-28
DK2800557T3 (da) 2021-02-15
PH12014501446A1 (en) 2014-10-08
WO2013103318A1 (en) 2013-07-11
BR112014016624A2 (pt) 2017-06-13
AU2013206983A1 (en) 2014-07-03
PH12014501446B1 (en) 2014-10-08
MX370218B (es) 2019-12-05
ZA201405745B (en) 2016-06-29
EP2800557A1 (en) 2014-11-12
CA2862497C (en) 2020-04-14
AU2013206983B2 (en) 2017-10-05
HK1201448A1 (en) 2015-09-04
JP6169609B2 (ja) 2017-07-26
RU2014132174A (ru) 2016-02-27
JP2015503581A (ja) 2015-02-02
US20130177646A1 (en) 2013-07-11
CN104053433A (zh) 2014-09-17

Similar Documents

Publication Publication Date Title
AR089670A1 (es) Forma de dosificacion que comprende nicotina solida con reduccion de los trastornos organolepticos
CL2016001544A1 (es) Composición dentífrica que comprende óxido de zinc y citrato de zinc
MX2015014656A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
EP3448521C0 (en) CHEWING GUM COMPOSITION COMPRISING CANNABINOIDS AND NICOTINE
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
IL264065A (en) Oral gastroretentive formulations and uses thes thereof
CL2015001914A1 (es) Composicion farmaceutica de liberacion demorada que comprende una forma de liberacion oral que tiene un nucleo que comprende un compuesto de biguanida y un recubrimiento enterico; y metodos para reducir eventos adversos de los compuestos, tratar trastornos metabolicos, reducir el inicio de la diabetes e inducir perdida de peso.
ECSP17084331A (es) Formulaciones farmacéuticas
CO2018008207A2 (es) Composiciones para el cuidado bucal y métodos para utilizar las composiciones
AR128816A2 (es) Formas de dosificación farmacéutica de perlas de cisteamina
MX2017000254A (es) Sistema para la administracion de una composicion de higiene bucal.
EP3035933A4 (en) Compositions and therapeutic methods for accelerated plaque regression
BRPI0906466A2 (pt) Composição para cuidado oral, e, métodos para preparar uma composição oral, e para aplicar uma quantidade eficaz da composição oral
MX2013011336A (es) Composiciones farmaceuticas intranasales de benzodiazepina.
MX2015009269A (es) Composiciones farmaceuticas que comprenden donadores de nitroxilo.
CL2016002560A1 (es) Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación.
BR112015030140A2 (pt) forma de dosagem farmacêutica sólida para liberação de pelo menos um ingrediente farmacêutico ativo na cavidade oral
ECSP088727A (es) Forma galénica divisible que permite una liberación modificada del principio activo
CO6801754A2 (es) Una composición farmacéutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
EP3035934A4 (en) Compositions and therapeutic methods for accelerated plaque regression
CL2015002181A1 (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod.
EP3826627C0 (de) Oral applizierbare pharmazeutische darreichungsform mit modifizierter freisetzung
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
PL2956011T3 (pl) Kompozycja do żucia do podawania doustnego i sposób jej wytwarzania

Legal Events

Date Code Title Description
FB Suspension of granting procedure